MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

MDT

98.04

-0.23%↓

VEEV

301.51

-1.09%↓

A

142.09

+2.42%↑

HQY

91.65

+4.35%↑

PHR.US

23.47

-0.34%↓

Search

Organon & Co

Atvērts

SektorsVeselības aprūpe

10.21 -3.22

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

10.25

Max

10.76

Galvenie mērījumi

By Trading Economics

Ienākumi

-174M

-87M

Pārdošana

81M

1.6B

P/E

Sektora vidējais

4.03

35.739

EPS

1

Dividenžu ienesīgums

7.81

Peļņas marža

-5.443

Darbinieki

10,000

EBITDA

124M

449M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+36.79% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

7.81%

3.08%

Nākamie ieņēmumi

2025. g. 30. okt.

Nākamais dividenžu datums

2025. g. 11. dec.

Nākamais Ex dividenžu datums

2025. g. 11. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

304M

2.8B

Iepriekšējā atvēršanas cena

13.43

Iepriekšējā slēgšanas cena

10.21

Ziņu noskaņojums

By Acuity

50%

50%

183 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Organon & Co Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 7. okt. 16:58 UTC

Peļņas

BMW Trims 2025 View, Citing Weaker Performance in China

2025. g. 7. okt. 23:43 UTC

Tirgus saruna

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025. g. 7. okt. 23:36 UTC

Tirgus saruna

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025. g. 7. okt. 23:19 UTC

Tirgus saruna

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 22:50 UTC

Tirgus saruna

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025. g. 7. okt. 22:40 UTC

Tirgus saruna

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 7. okt. 21:56 UTC

Tirgus saruna

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025. g. 7. okt. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 20:44 UTC

Karstas akcijas

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025. g. 7. okt. 19:42 UTC

Tirgus saruna

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025. g. 7. okt. 19:23 UTC

Iegādes, apvienošanās, pārņemšana

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025. g. 7. okt. 19:07 UTC

Tirgus saruna

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025. g. 7. okt. 19:02 UTC

Tirgus saruna

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 7. okt. 16:20 UTC

Tirgus saruna

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025. g. 7. okt. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 7. okt. 15:37 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 15:37 UTC

Tirgus saruna

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025. g. 7. okt. 15:33 UTC

Tirgus saruna

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025. g. 7. okt. 15:25 UTC

Tirgus saruna

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025. g. 7. okt. 15:15 UTC

Tirgus saruna

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025. g. 7. okt. 15:04 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 7. okt. 15:04 UTC

Tirgus saruna

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025. g. 7. okt. 14:56 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 7. okt. 14:56 UTC

Tirgus saruna

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025. g. 7. okt. 14:52 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Organon & Co Prognoze

Cenas mērķis

By TipRanks

36.79% augšup

Prognoze 12 mēnešiem

Vidējais 14.5 USD  36.79%

Augstākais 18 USD

Zemākais 11 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Organon & Co — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

1

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

8.53 / 9.18Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

183 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
help-icon Live chat